SG11201901505SA - I domain chimeric antigen receptor specific to icam-1 - Google Patents
I domain chimeric antigen receptor specific to icam-1Info
- Publication number
- SG11201901505SA SG11201901505SA SG11201901505SA SG11201901505SA SG11201901505SA SG 11201901505S A SG11201901505S A SG 11201901505SA SG 11201901505S A SG11201901505S A SG 11201901505SA SG 11201901505S A SG11201901505S A SG 11201901505SA SG 11201901505S A SG11201901505S A SG 11201901505SA
- Authority
- SG
- Singapore
- Prior art keywords
- icam
- international
- domain
- car
- human
- Prior art date
Links
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title abstract 9
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title abstract 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102100022339 Integrin alpha-L Human genes 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383139P | 2016-09-02 | 2016-09-02 | |
| US201662419817P | 2016-11-09 | 2016-11-09 | |
| PCT/US2017/046630 WO2018052594A1 (en) | 2016-09-02 | 2017-08-11 | I domain chimeric antigen receptor specific to icam-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901505SA true SG11201901505SA (en) | 2019-03-28 |
Family
ID=61281980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901505SA SG11201901505SA (en) | 2016-09-02 | 2017-08-11 | I domain chimeric antigen receptor specific to icam-1 |
Country Status (10)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018044534A1 (en) * | 2016-09-02 | 2018-03-08 | Cornell University | Transduced t cells expressing human sstr2 and application thereof |
| EP3571221A2 (en) | 2017-01-20 | 2019-11-27 | Juno Therapeutics GmbH | Cell surface conjugates and related cell compositions and methods |
| EP3607319A1 (en) * | 2017-04-07 | 2020-02-12 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| WO2022126084A1 (en) * | 2020-12-09 | 2022-06-16 | Affyimmune Therapeutics, Inc. | Dual chimeric antigen receptor targeting epcam and icam-1 |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| EP4587067A1 (en) * | 2022-09-14 | 2025-07-23 | Biosceptre (Aust) Pty Ltd | In vivo detection of immune cells |
| US12385818B2 (en) | 2023-02-14 | 2025-08-12 | Saudi Arabian Oil Company | Modeling gas desorption in a subsurface reservoir |
| WO2024206155A1 (en) | 2023-03-24 | 2024-10-03 | Cornell University | Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2204183A1 (en) | 1994-11-01 | 1996-05-09 | Andrew Lawrence Feldhaus | Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| AU4418900A (en) | 1999-04-16 | 2000-11-02 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| AU7541101A (en) * | 2000-06-09 | 2001-12-24 | Bristol Myers Squibb Co | Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| US7176187B2 (en) | 2001-02-15 | 2007-02-13 | Board Of Regents, The University Of Texas System | Fusion proteins based upon somatostatin receptors |
| WO2007070488A2 (en) | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| CA2810838C (en) * | 2010-09-08 | 2021-07-06 | The Board Of Regents Of The University Of Texas System | Somatostatin receptor-based cancer therapy |
| CN104126009B (zh) | 2011-10-07 | 2019-05-10 | 国立大学法人三重大学 | 嵌合抗原受体 |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2016152786A1 (ja) * | 2015-03-20 | 2016-09-29 | 国立大学法人三重大学 | 細胞傷害性ｔ細胞放出エキソソームによる癌間質間葉系細胞を標的とした腫瘍増殖及び転移抑制に係る治療薬 |
| WO2018044534A1 (en) * | 2016-09-02 | 2018-03-08 | Cornell University | Transduced t cells expressing human sstr2 and application thereof |
-
2017
- 2017-08-11 WO PCT/US2017/046618 patent/WO2018044534A1/en active Application Filing
- 2017-08-11 CA CA3033846A patent/CA3033846A1/en active Pending
- 2017-08-11 SG SG11201901505SA patent/SG11201901505SA/en unknown
- 2017-08-11 KR KR1020197009375A patent/KR102613109B1/ko active Active
- 2017-08-11 US US15/675,419 patent/US10577408B2/en active Active
- 2017-08-11 EP EP17851258.8A patent/EP3522718B1/en active Active
- 2017-08-11 JP JP2019512782A patent/JP6996772B2/ja active Active
- 2017-08-11 ES ES17851258T patent/ES2971550T3/es active Active
- 2017-08-11 CN CN201780004619.1A patent/CN108697096B/zh active Active
- 2017-08-11 AU AU2017325678A patent/AU2017325678B2/en active Active
- 2017-08-11 US US15/675,508 patent/US10428136B2/en active Active
- 2017-08-11 WO PCT/US2017/046630 patent/WO2018052594A1/en unknown
-
2019
- 2019-09-25 US US16/582,206 patent/US11046748B2/en active Active
-
2020
- 2020-02-11 US US16/787,539 patent/US11634471B2/en active Active
-
2023
- 2023-03-21 US US18/187,268 patent/US12325736B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102613109B1 (ko) | 2023-12-13 |
| US20180066035A1 (en) | 2018-03-08 |
| CN108697096B (zh) | 2022-05-03 |
| US10428136B2 (en) | 2019-10-01 |
| JP2019530441A (ja) | 2019-10-24 |
| EP3522718B1 (en) | 2023-07-05 |
| US20230265165A1 (en) | 2023-08-24 |
| US20180066037A1 (en) | 2018-03-08 |
| WO2018052594A1 (en) | 2018-03-22 |
| AU2017325678B2 (en) | 2022-03-17 |
| US20210309721A1 (en) | 2021-10-07 |
| US12325736B2 (en) | 2025-06-10 |
| JP6996772B2 (ja) | 2022-02-21 |
| US10577408B2 (en) | 2020-03-03 |
| CA3033846A1 (en) | 2018-03-22 |
| WO2018044534A1 (en) | 2018-03-08 |
| CN108697096A (zh) | 2018-10-23 |
| US11634471B2 (en) | 2023-04-25 |
| US20200181238A1 (en) | 2020-06-11 |
| ES2971550T3 (es) | 2024-06-05 |
| EP3522718A1 (en) | 2019-08-14 |
| EP3522718A4 (en) | 2020-02-19 |
| US20200017573A1 (en) | 2020-01-16 |
| AU2017325678A1 (en) | 2019-03-14 |
| KR20190057072A (ko) | 2019-05-27 |
| US11046748B2 (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901505SA (en) | I domain chimeric antigen receptor specific to icam-1 | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201810161RA (en) | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins |